Gamco Investors INC. ET AL Sells 3,473 Shares of Eli Lilly and Company $LLY

Key Points

• Gamco Investors INC. ET AL reduced its stake in Eli Lilly and Company by 10.4%, selling 3,473 shares in the first quarter, resulting in holdings valued at approximately $24.8 million.
• Eli Lilly's stock has shown strong performance, with a recent quarterly revenue of $15.56 billion, up 37.6% year-over-year, and an earnings per share (EPS) of $6.31 surpassing estimates by $0.72.
• The company declared a quarterly dividend of $1.50 per share, reflecting an annualized yield of 0.9%, with a payout ratio of 39.22%.

Gamco Investors INC. ET AL lowered its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 10.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 30,070 shares of the company's stock after selling 3,473 shares during the period. Gamco Investors INC. ET AL's holdings in Eli Lilly and Company were worth $24,835,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of LLY. WestEnd Advisors LLC lifted its stake in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares in the last quarter. Citizens National Bank Trust Department lifted its stake in Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new stake in Eli Lilly and Company in the 1st quarter worth $40,000. Mascagni Wealth Management Inc. purchased a new stake in Eli Lilly and Company in the 4th quarter worth $43,000. Finally, O Brien Wealth Partners LLC lifted its stake in Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after purchasing an additional 12 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $696.08 on Tuesday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company's 50-day simple moving average is $752.46 and its two-hundred day simple moving average is $788.70. Eli Lilly and Company has a one year low of $623.78 and a one year high of $972.48. The company has a market capitalization of $658.81 billion, a P/E ratio of 45.50, a P/E/G ratio of 0.99 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the firm earned $3.92 earnings per share. The company's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.9%. Eli Lilly and Company's dividend payout ratio is presently 39.22%.

Insiders Place Their Bets

In related news, EVP Daniel Skovronsky purchased 1,000 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. This represents a 0.73% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Gabrielle Sulzberger purchased 117 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.14% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have commented on LLY shares. DZ Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Wall Street Zen upgraded shares of Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research report on Friday. Finally, UBS Group decreased their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $950.17.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.